Literature DB >> 10337023

Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery.

A E Sousa1, A F Chaves, M Doroana, F Antunes, R M Victorino.   

Abstract

Fas, CD40L and OX40 are members of the tumour necrosis factor (TNF) receptor superfamily with critical roles in T cell activation and death, B cell function, dendritic cell maturation and leucocyte traffic regulation. The aim of this study was to evaluate the effects of anti-retroviral therapy (HAART) on CD40L, OX40 and Fas expression on freshly isolated peripheral blood T cells by three-colour flow cytometry and compare them with lymphoproliferative responses, peripheral blood cell counts and viral load. Fourteen asymptomatic HIV-1+ patients treated with Lamivudine, Stavudine and Nelfinavir were prospectively investigated sequentially for 48 weeks. At baseline, patients exhibited significantly enhanced proportions and counts of CD40L+ and OX40+ cells within the CD4 subset which were corrected by weeks 8-16 of HAART. Interestingly, in the five patients showing viral load rebound during therapy in spite of increasing CD4 counts, the reduction of the levels of these costimulatory molecules was similarly maintained. Therapy induced a decrease in the over-expression of Fas, particularly in the CD4 subset where normal levels were reached at week 8. This reduction occurred in parallel with the major recovery of lymphoproliferative responses. Higher basal levels and lower reduction of Fas were associated with suboptimal suppression of viraemia. In conclusion, this previously undescribed increased expression of CD40L and OX40 may play a role in the HIV-associated pan-immune activation and represent a possible target for immunointervention, as suggested for several immunologically mediated diseases. Moreover, HAART induced an early correction of the over-expression of Fas, CD40L and OX40 in CD4 T cells which could be involved in the recovery of the cell traffic disturbances and in the T cell renewal capacity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10337023      PMCID: PMC1905269          DOI: 10.1046/j.1365-2249.1999.00872.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production.

Authors:  A Desai-Mehta; L Lu; R Ramsey-Goldman; S K Datta
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

2.  Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis.

Authors:  A D Weinberg; D N Bourdette; T J Sullivan; M Lemon; J J Wallin; R Maziarz; M Davey; F Palida; W Godfrey; E Engleman; R J Fulton; H Offner; A A Vandenbark
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

Review 3.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

4.  Distinct alterations in the distribution of CD45RO+ T-cell subsets in HIV-2 compared with HIV-1 infection.

Authors:  A C Jaleco; M J Covas; L A Pinto; R M Victorino
Journal:  AIDS       Date:  1994-12       Impact factor: 4.177

5.  Cross-linking of the CD40 ligand on human CD4+ T lymphocytes generates a costimulatory signal that up-regulates IL-4 synthesis.

Authors:  M H Blotta; J D Marshall; R H DeKruyff; D T Umetsu
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

6.  Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression.

Authors:  M L Gougeon; H Lecoeur; A Dulioust; M G Enouf; M Crouvoiser; C Goujard; T Debord; L Montagnier
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

7.  The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response.

Authors:  E Stüber; W Strober
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

8.  The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells.

Authors:  A Imura; T Hori; K Imada; T Ishikawa; Y Tanaka; M Maeda; S Imamura; T Uchiyama
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

9.  Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals.

Authors:  M J Yellin; J Brett; D Baum; A Matsushima; M Szabolcs; D Stern; L Chess
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

10.  Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals.

Authors:  P D Katsikis; E S Wunderlich; C A Smith; L A Herzenberg; L A Herzenberg
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Expanding role of circulating adhesion molecules in assessing prognosis and treatment response in human immunodeficiency virus infection.

Authors:  Nikolaos V Sipsas; Petros P Sfikakis
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

2.  OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection.

Authors:  Y Takahashi; Y Tanaka; A Yamashita; Y Koyanagi; M Nakamura; N Yamamoto
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4(+) T-cell counts.

Authors:  Nikolaos V Sipsas; Petros P Sfikakis; Athanasios Kontos; Theodore Kordossis
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

4.  Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection.

Authors:  M-A Jenabian; M Patel; I Kema; K Vyboh; C Kanagaratham; D Radzioch; P Thébault; R Lapointe; N Gilmore; P Ancuta; C Tremblay; J-P Routy
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

5.  Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group.

Authors:  A Amendola; F Poccia; F Martini; C Gioia; V Galati; M Pierdominici; M Marziali; F Pandolfi; V Colizzi; M Piacentini; E Girardi; G D'offizi
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 6.  Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.

Authors:  Shahram Salek-Ardakani; Michael Croft
Journal:  J Interferon Cytokine Res       Date:  2010-04       Impact factor: 2.607

7.  CD40-CD40L interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus encephalitis and multiple sclerosis.

Authors:  Teresa G D'Aversa; Karen M Weidenheim; Joan W Berman
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

8.  Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals.

Authors:  Susan Moir; Kisani M Ogwaro; Angela Malaspina; Joshua Vasquez; Eileen T Donoghue; Claire W Hallahan; Shuying Liu; Linda A Ehler; Marie A Planta; Shyamasundaran Kottilil; Tae-Wook Chun; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

9.  Human immunodeficiency virus (HIV) type 1 Vpu induces the expression of CD40 in endothelial cells and regulates HIV-induced adhesion of B-lymphoma cells.

Authors:  Winnie W Henderson; Rebecca Ruhl; Paul Lewis; Matthew Bentley; Jay A Nelson; Ashlee V Moses
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction.

Authors:  Norbert Donhauser; Kathrin Pritschet; Martin Helm; Thomas Harrer; Philipp Schuster; Moritz Ries; Georg Bischof; Jörg Vollmer; Sigrun Smola; Barbara Schmidt
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.